 Hey what's up guys it's Chicago trader here for I believe week six of the fundamental analysis series I'm going to be covering MLNT and it's been a while since I've had kind of a company come up that interested me in the kind of longer term big picture kind of what's going on you know kind of play for a swing possibility for myself again not you know investment advice do your own DD so this one happened to move it's MLNT Melinda Therapeutics so it's kind of what I'm going to try to do on this one is go through a little bit of what I did last week and then kind of try to piece together the whole picture and kind of you know how I get more of a holistic view from kind of a top-down approach when it comes to kind of researching these things and whatnot so let me just jump right into it so right here obviously we have a $1.75 price per share 100 million dollar market cap so I'm going to jump right to the most recent 10 Q so actually before I do that we'll see here if I'm going to look at the you know the first thing like I said last week I'm kind of jumping through here look at the outstanding shares just a quick glance so there's 31 million on March 2nd I punched up to May 2nd 31 million so no delusion Q2 there's a jump as of August 8th there's 56 it's cash 83 million on October 1st 165 million in assets so it's nice to see a biotech you know not terrible they have some inventory some other assets minus cash I can't remember what off the top of my head I went over last week but a lot of these biotechs the only assets they have are cash but not a lot of debt current liabilities 123 million so you know after you take the cash and burnt now which I get into here in a second it's about even for current liabilities the networking capital as you can see I have it here at about $10 million a month networking capitals even I always do update the cash right so the cash that we're looking at in Q3 was as of October 1st so it's about 45 47 million as of the beginning of February for using that rate what else we got here yeah high institutional ownership about 70 percent according to FinViz obviously when I punch back through those you know they don't put out a lot of 8k's and you know in the last year they've had four or five but when I bring these up so this one was the one that caught my attention so here's the data here on the side of this is December 19th of 2018 they enter this agreement with Viterra VHP for a $75 million purchase agreement that's where essentially this VHP will buy shares when the company Melinta MLNT tells them to essentially so then it comes back here and it says look a month later they enter into a commitment letter for $135 million of a convertible loan facility